查詢結果分析
相關文獻
- Roflumilast用於慢性阻塞性肺病治療
- Roflumilast (Daxas®)選擇性PDE4抑制劑
- 腹直肌鞘血腫合併慢性阻塞性肺病: 病例報告
- Lung Volume Reduction Surgery--A Case Report
- Ariflo[fef0]--A Brief Report on a New Second-Generation Phosphodiesterase 4 Inhibitor
- Acute Chronic Respiratory Failure Complicated by Undetected Obstructive Sleep Apnea Syndrome
- 護理一位慢性阻塞性肺病個案之經驗
- 慢性阻塞性肺病的復健工作
- A Multidisciplinary Pulmonary Rehabilitation Program for Patients with Moderately Severe Chronic Obstructive Pulmonary Disease
- Agrobacterium Radiobacter Bacteremia in a Patient with Chronic Obstructive Pulmonary Disease
頁籤選單縮合
題 名 | Roflumilast用於慢性阻塞性肺病治療=Roflumilast in COPD Managements |
---|---|
作 者 | 邵時傑; 葉鳳英; 李政宏; | 書刊名 | 藥學雜誌 |
卷 期 | 29:4=117 2013.12[民102.12] |
頁 次 | 頁127-132 |
分類號 | 418.2216 |
關鍵詞 | 慢性阻塞性肺病; PDE4抑制劑; Roflumilast; COPD; PDE4 inhibitor; |
語 文 | 中文(Chinese) |
中文摘要 | GOLD (Global Initiatives for Chronic Obstructive Lung Disease)治療指引指出,重度慢性阻塞性肺病 (chronic obstructive lung disease, COPD),並伴隨頻繁惡化病史的成年慢性支氣管病人,可使用 PDE4 (phosphodieasterase 4,磷酸二酯酶 4)抑制劑作為藥物治療。 Roflumilast為目前唯一上市的口服 PDE4抑制劑,藉由抑制呼吸道慢性發炎來達到治療療效。臨床試驗雖發現 roflumilast可顯著改善重度 COPD病人肺功能和減少急性惡化發生,但卻有精神狀態改變和體重下降的副作用疑慮。目前各國醫療科技評估 (health technology assessment, HTA)於衡量療效與安全性後,均不建議收載給付。 |
英文摘要 | According to GOLD (Global Initiatives for Chronic Obstructive Lung Disease) guidelines, PDE (phosphodieasterase) 4 inhibitors should be used in COPD (chronic obstructive lung disease) patients with patients with the history of exacerbations, chronic bronchitis and severe or very severe airflow limitation. Roflumilast was the PDE4 inhibitor with anti-inflammatory effect, and it can significantly improve lung functions and reduced acute exacerbations in COPD patients from results of clinical trials. However, psychiatric side effects and weight loss were warranted clinical attentions. With reports of HTA (health technology assessment) from different countries, roflumilast was not reimbursed due to inadequate risk-benefit information. |
本系統中英文摘要資訊取自各篇刊載內容。